glp-1 cirrhosis Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective GLP-1 Agonists May Lower Cirrhosis,

Participants received the drug for 12 months and/or continued to take their standard of care medication, such as l-DOPA

While these medications have led to remarkable weight loss, in some cases the loss has been so extreme that patients develop severe facial fat reduction, giving them a skeletal appearance

Before the data were analyzed thematically, the interviews were recorded and transcribed

These compounds may contribute to changes in urine smell, particularly if weight loss is rapid or substantial

Updated January 30, 2026

Phytobezoar associated with levodopa-carbidopa intestinal gel infusion in patients with Parkinsons Disease: a case report and literature review